GERN - Geron Corp

Day	1m	10m	60m	PreMarket	Market	AfterHours	Gap
1.27 0.0 (0.0%)	---	---	0.0 (-0.39%)	0.01 (0.79%)	0.0 (0.39%)	-0.02 (-1.55%)	-0.02 (-1.55%)

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Category: PHARMACEUTICAL PREPARATIONS

Market Period: AfterHours

Earnings & Ratios

Basic EPS:: -0.02
Diluted EPS:: -0.02
Basic P/E:: -63.5
Diluted P/E:: -63.5
RSI(14) 1m:: 33.33
VWAP:: 1.27
RVol:: 1.2869

Events

Period	Kind	Movement	Occurred At
1m	Price decrease 1m	1.28 -0.02 (-1.35%)	Oct 15 14:37
1m	Price decrease 1m	1.26 -0.02 (-1.56%)	Oct 15 10:42
1m	Price decrease 1m	1.29 -0.01 (-1.15%)	Oct 15 10:11
1m	Price increase 1m	1.29 +0.02 (+1.57%)	Oct 15 09:41